ESMO Breast 2024 | Updated findings of T-DXd in DESTINY-Breast02 at ESMO Breast 2024

Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, discusses the updated results from the Phase III DESTINY-Breast02 trial (NCT03523585) of trastuzumab deruxtecan (T-DXd) against physician’s choice in patients with HER2+ metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1). Progression-free survival and overall survival were still significantly improved in patients receiving T-DXd and adverse events remain manageable in this cohort. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.